Everything below concerns Investigational drug. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-22. Numbers and descriptions here follow the published literature rather than marketing material.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a metabolic modulator. |
| Approved medical use | None in major jurisdictions | Not a registered drug. |
| Common test matrix | Urine | Most anti-doping samples use urine. |
| Typical detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Reference standard storage | -20 °C, desiccated | Typical for analytical standards. |
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
==== Monoclonal antibodies ==== Monoclonal antibodies have long been considered for OI, but as of 2021, such therapy has not been approved for OI, neither in the European Union nor in the United States. Thus, it is unclear whether they are safe or effective. Among the monoclonal antibodies that have been studied are romosozumab (targets sclerostin, by Amgen), fresolimumab (TGF-β, Sanofi), blosozumab (sclerostin, Lilly), and setrusumab (sclerostin, begun by Novartis). Setrusumab, formerly known as BPS-804, is a monoclonal antibody that targets sclerostin, and has been studied in OI specifically more than any of the others. In the body, sclerostin binds to the LRP5 and LRP6 receptors, resulting in inhibition of the Wnt signaling pathway. This decreases bone formation, and is not a problem when a person has healthy bones. It is thought, though, that decreasing the concentration of sclerostin in the body may lead to the formation of more bone, and that is the premise as to why monoclonal antibodies that reduce the concentrations of naturally occurring sclerostin may help strengthen OI bone. While setrusumab was first developed at the pharmaceutical company Novartis, Novartis sold its rights to patent the drug to Mereo Biopharma in 2015, who has continued its development in conjunction with Ultragenyx. In 2019, Mereo announced that it had concluded collecting data for its phase II-B trial of setrusumab; the study was completed on 12 November 2020.
Rubidium is a very soft, ductile, silvery-white metal. It has a melting point of 39.3 °C (102.7 °F) and a boiling point of 688 °C (1,270 °F). It forms amalgams with mercury and alloys with gold, iron, caesium, sodium, and potassium, but not lithium (despite rubidium and lithium being in the same periodic group). Rubidium and potassium show a very similar purple color in the flame test, and distinguishing the two elements requires more sophisticated analysis, such as spectroscopy.
== Names == The initial strikes on Iran were codenamed Operation Epic Fury by the United States government, and Operation Roaring Lion by the Israeli government, in line with their codename of Operation Rising Lion for their strikes on Iran during the Twelve-Day War in June 2025. Iran codenamed its response Operation True Promise IV (Persian: عملیات وعده صادق ۴, romanized: Amaliyat-e Va'deh-ye Sadegh 4). American media outlets have generally referred to the conflict as the Iran war. The war has also been referred to by some outlets as the "Third Gulf War" (Gulf War III), following the Gulf War (1990–1991), and the Iraq War/Second Gulf War (Gulf War II) (2003–2011). Iranian state media has referred to the conflict as the "Third Imposed War", with the Iran–Iraq War (1980–1988) and the Twelve-Day War respectively as the "First" and "Second". Due to the war starting during the month of Ramadan, it has sometimes been called the "Ramadan War". The American codename morphed into "Operation Epstein Fury", which became popularized across many social media platforms and also drew criticism from the ADL.
In 2022, Peña ran successfully to stand as the Colorado Party's presidential candidate; he was widely seen as the candidate most closely aligned to former president Horacio Cartes, while his opponent, Arnoldo Wiens, was aligned with Abdo Benítez. Critics of Peña have said that if elected president, Horacio Cartes would be a grey eminence and that Peña would merely act as a mouthpiece for Cartes, who is sanctioned by the U.S. as "significantly corrupt". Colorado Party politician Blanca Ovelar said Peña would end up acting as a "secretary" to Cartes if he was elected. Cartes and his supporters in Congress had previously attempted to pass a constitutional amendment to allow Cartes to run for re-election, sparking riots in the country. Peña was elected President of Paraguay, after winning 43.9% of the vote in the 2023 general election in April, defeating his closest rival Efraín Alegre by a difference of 15 percentage points. He was congratulated by outgoing president Mario Abdo Benítez, and presidents Luiz Inácio Lula da Silva of Brazil and Alberto Fernández of Argentina. Peña called for unity to address the economic challenges the country is currently facing. Peña was inaugurated on 15 August 2023. At 44 years old, he became Paraguay's youngest president since the restoration of democracy in 1989, surpassing Abdo Benítez, who was 46 when he assumed the role in 2018. On 28 September 2025, protests began in Paraguay against Peña's government.
Sources: en.wikipedia.org
is the unit tensor. This equation can be thought of as a generalized form of Newton's law of viscosity. The bulk viscosity (also called volume viscosity) expresses a type of internal friction that resists the shearless compression or expansion of a fluid. Knowledge of
Javits (1952), former ambassador and permanent U.S. representative to the Conference on Disarmament in Geneva 2001–2003; U.S. permanent representative to the Organisation for the Prohibition of Chemical Weapons 2003–2009 James D. Theberge (1952), former U.S. ambassador to Chile and Nicaragua G. Norman Anderson (1954), former U.S. ambassador to Sudan David J. Bardin (1954), deputy administrator of the Federal Energy Administration; commissioner of the New Jersey Department of Environmental Protection William Haddad (1954), political operative, lobbyist, and journalist, Peace Corps founding official, aide to the Kennedy family, and grandson-in-law of Franklin D. Roosevelt Richard E. Benedick (1955), president emeritus of the National Council for Science and the Environment, ambassador, and chief U.S. negotiator to the Montreal Protocol John L. Hirsch (1957), U.S. ambassador to Sierra Leone 1995–1998 Morton Halperin (1958), deputy assistant secretary of defense, director of policy planning for the U.S. State Department, and member of Richard Nixon's Enemies List Shelby Brewer (1959), assistant secretary of energy for nuclear energy 1981–1984 Benjamin Huberman (1959), acting director of the Office of Science and Technology Policy; acting science advisor to the president in 1981 Pat Mullins (1959), chairman of the Republican Party of Virginia Constantine Menges (1960), national security aide to Ronald Reagan James E.
=== Laboratory Network === Gift of Hope Organ and Tissue Donor Network Laboratory (Itasca) HSHS St. Mary's Hospital Decatur, IL Illinois State University Loyola University Medical Center SHIELD Illinois Clinical Diagnostic Laboratory at UIC SHIELD Illinois COVID-19 Testing Lab (Springfield) SHIELD T3 Kentucky SHIELD T3 Madison SHIELD T3 UIC Simple Labs University of Illinois College of Medicine Rockford University of Illinois Urbana-Champaign Annex
Bio-Synthesis, Inc. (BSI) is a biotechnology company headquartered in Lewisville, Texas. It is a provider of custom and catalog peptides, custom oligos, antibodies, organic synthesis, and analytical services. Biomedical researchers worldwide in universities, biotech companies, private clinics, and government agencies use products from Bio-Synthesis, Inc. in studies ranging from PCR diagnostics to cancer research and the Human Genome Project.
=== Self-assembly === The self-assembly technique is used to generate peptide nanofibers and peptide amphiphiles. The method was inspired by the natural folding process of amino acid residues to form proteins with unique three-dimensional structures. The self-assembly process of peptide nanofibers involves various driving forces such as hydrophobic interactions, electrostatic forces, hydrogen bonding and van der Waals forces and is influenced by external conditions such as ionic strength and pH.
Sources: en.wikipedia.org
Legal status varies by country, but cardarine is not approved as a medicine in major jurisdictions. It is often sold as a research chemical, a category that may not be lawful for human use. Buyers should check local laws and product labels carefully.
Anti-doping laboratories use LC-MS/MS to detect GW501516 and its metabolites, usually in urine. The method can identify the parent compound at low concentrations. Detection windows vary with dose and individual factors.
No, cardarine has no approved medical uses in major jurisdictions. Early research explored metabolic conditions, but those programs were discontinued. It is not a registered treatment for any disease.
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.